It's fraudulent for academics to give their names to medical articles ghostwritten by pharmaceutical industry writers, say two Canadian law professors who call for potential legal sanctions.As always, there is room for compromise:
Studies suggest that industry-driven drug trials and industry-sponsored publications are more likely to downplay a drug's harms and exaggerate a drug's virtues, said Trudo Lemmens, a law professor at the University of Toronto. The integrity of medical research is also harmed by ghostwritten articles, he said.
Linda Logdberg of Fernbank Science Center in Atlanta wrote a second commentary. Logdberg worked in the medical communication industry for 11 years, and she offered her personal view of her work and why she did it.THAT WILL FIX IT.
Logdberg proposes eliminating the middlemen between drug companies and doctors by having pharmaceutical companies employ medical writers to work directly with researchers. The pharmaceutical company's role would be limited to fact-checking and related topics, meaning drug promotion would still happen, but would be in the hands of advertising agencies alone.